---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-003928"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:52:16.415262+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology board changes: Vlad resigns, Theagène elected, Smith joins audit committee

## Summary
- Laurentiu Vlad resigned as Class III director and audit committee member effective March 16, 2023, citing personal reasons; no disagreement with the company.
- Jean-Manassé Theagène elected as Class III director to fill the vacancy, effective March 17, 2023, until the 2025 annual meeting.
- Stan Smith appointed to the audit committee on March 16, 2023, filling the vacancy from Vlad's resignation.
- Theagène will receive standard independent director compensation and enter into an indemnification agreement with the company.

## SEC filing metadata
- accession: 0001564590-23-003928
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000156459023003928/0001564590-23-003928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000156459023003928/maia-8k_20230313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-003928
- JSON: https://secwatch.observer/filing/0001564590-23-003928.json
- Plain text: https://secwatch.observer/filing/0001564590-23-003928.txt

## Key facts
- Executive change
  Jean-Manassé Theagène was elected as Class III Director at MAIA Biotechnology, Inc..
  - Action: elected
  - Role: Class III Director
  source text: On March 17, 2023, upon the recommendation of the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Board, the Board elected Jean-Manassé Theagène to serve as a Class III director of the Board, with immediate effect, until the Company’s 2025 annual meeting of stockholders, or until such time as he resigns or is removed, and his successor has been elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459023003928/0001564590-23-003928-index.htm
- Executive change
  Laurentiu Vlad resigned as Class III Director and Audit Committee Member at MAIA Biotechnology, Inc..
  - Action: resigned
  - Role: Class III Director and Audit Committee Member
  source text: On March 13, 2023, Laurentiu Vlad notified MAIA Biotechnology, Inc. (the “Company”) that he is resigning from the Board of Directors (the “Board”) of the Company effective on March 16, 2023, due to personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459023003928/0001564590-23-003928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.